Screener
Agios Pharmaceuticals AGIO Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands) | Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value |
|---|---|---|---|---|
| Corporate debt securities | 332,977 | 100 | (264) | 332,813 |
| Total current | 518,056 | 206 | (333) | 517,929 |
| Non-current: | ||||
| U.S. Treasuries | 155,754 | 15 | (951) | 154,818 |
| Government securities | 57,467 | 17 | (220) | 57,264 |
| Corporate debt securities | 135,701 | 2 | (531) | 135,172 |
| Total non-current | 348,922 | 34 | (1,702) | 347,254 |
| Total marketable securities | $866,978 | $240 | $(2,035) | $865,183 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's unrealized losses on investments (before tax)?
- Agios Pharmaceuticals (AGIO) reported unrealized losses on investments (before tax) of $333K in Q2 2026.
- How has Agios Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
- Agios Pharmaceuticals's unrealized losses on investments (before tax) decreased by 54.9% year-over-year, from $738K to $333K.
- What is the long-term trend for Agios Pharmaceuticals's unrealized losses on investments (before tax)?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's unrealized losses on investments (before tax) has grown at a -39.9% compound annual growth rate (CAGR), from $216K to $17K.
Ask your AI about Agios Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude